Drug design, development and therapy

Risk of New Dementia in COVID-19 Survivors with Type 2 Diabetes Using GLP-1 Receptor Agonists Compared to DPP-4 Inhibitors

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Type 2 diabetes mellitus (T2DM) and COVID-19 are each linked to an increased risk of dementia.

  • COVID-19 survivors with T2DM may face compounded risks due to the coexistence of metabolic, inflammatory, and vascular factors.
  • The relationship between antidiabetic treatment choices and dementia risk in patients with both T2DM and a history of COVID-19 is currently unclear.
  • Both T2DM and COVID-19 independently contribute to heightened dementia risk.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Oct '25
Glucagon-Like Peptide-1 Receptor Agonists and Lower Dementia Risk in Older Adults with Type 2 Diabetes
top 10% journal
cited by 4 papers
journal article
Dec '24
Kidney health in type 2 diabetes with moderate heart risk using four common diabetes medicines
top 5% journal
cited by 5 papers
journal article
Sep '24
SGLT2 Inhibitors and Their Link to Dementia Risk and Death in Older Adults with Type 2 Diabetes
top 5% journal
cited by 22 papers
journal article
Jul '26
Glucagon-Like Peptide-1 Drugs and Risk of Fragile Bone Fractures in Type 2 Diabetes
top 2% journal
Mar '26
Link between diabetes drugs targeting GLP-1 receptors and thigh bone fracture risk in type 2 diabetes
journal article
Feb '26
Risk of Heart Failure Hospitalization with GLP-1 Receptor Agonists Compared to DPP-4 or SGLT-2 Inhibitors in People with Type 2 Diabetes
top 1% journal
cited by 7 papers
journal article
Aug '26
Starting glucagon-like peptide-1 receptor agonists and the risk of new diabetic eye disease in type 2 diabetes patients
english abstract
Apr '26
Skin-related effects linked to glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a large-scale study
top 10% journal
randomized controlled trial
Mar '24
Real-World Effects of Weekly GLP-1 Medicines Compared to DPP-4 Inhibitors on Blood Sugar and Weight in Type 2 Diabetes
top 30% journal
cited by 10 papers
observational study
Dec '25
Use of GLP-1 Receptor Drugs and Epilepsy Risk in People with Type 2 Diabetes
top 5% journal
cited by 14 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
2 weeks ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
3 weeks ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
4 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
5 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
6 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
7 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
8 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
9 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
10 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
11 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief